Humacyte, Inc.
HUMA
$1.41
$0.021.44%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -4.26% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -4.26% | -- | -- | -- | -- |
| Cost of Revenue | 34.28% | 14.67% | -23.52% | -6.46% | -26.80% |
| Gross Profit | -35.60% | -12.41% | 26.81% | 7.73% | 29.23% |
| SG&A Expenses | -3.76% | 2.48% | 4.15% | 35.90% | 53.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.22% | 11.45% | -16.84% | 1.79% | -10.82% |
| Operating Income | -21.79% | -9.78% | 19.33% | -0.77% | 12.77% |
| Income Before Tax | -145.02% | -18.45% | 55.33% | 33.54% | 222.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -145.02% | -18.45% | 55.33% | 33.54% | 222.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -145.02% | -18.45% | 55.33% | 33.54% | 222.71% |
| EBIT | -21.79% | -9.78% | 19.33% | -0.77% | 12.77% |
| EBITDA | -23.85% | -10.53% | 20.75% | -0.53% | 13.86% |
| EPS Basic | -131.87% | 19.47% | 66.31% | 49.04% | 194.88% |
| Normalized Basic EPS | -35.98% | 67.10% | 45.02% | 20.66% | 68.08% |
| EPS Diluted | -132.19% | 19.47% | 66.31% | 49.52% | 194.88% |
| Normalized Diluted EPS | -36.25% | 67.10% | 45.02% | 20.66% | 68.15% |
| Average Basic Shares Outstanding | 50.46% | 47.09% | 32.58% | 30.43% | 21.48% |
| Average Diluted Shares Outstanding | 50.16% | 47.09% | 32.58% | 30.43% | 21.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |